CD8A and myeloid sarcoma: A number of clinical trials with monoclonal antibodies, specifically against CD4+ T cells [67], failed to show any therapeutic benefit in MS as opposed to broader spectrum antibodies (alemtuzumab CD52), which are able to deplete all T cells [68], including CD8+ T cells.